Literature DB >> 32269690

Pretreatment inflammatory indexes as prognostic predictors for survival in osteosarcoma patients.

Songwei Yang1, Chuncao Wu2, Liang Wang1, Dongli Shan1, Biao Chen1.   

Abstract

Pretreatment inflammatory indexes including neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) are associated with poor outcomes in various malignant tumors, but their prognostic value in patients with osteosarcoma is poorly known. This was a retrospective study of patients with osteosarcoma treated between 01/2010 and 12/2013 at Chongqing University Cancer Hospital. Follow-up was calculated from the date of initial histological diagnosis to December 2018 or death or loss of follow-up. Receiver operating characteristic (ROC) analysis was used to determine the NLR, LMR, PLR, and SII cut-off values (low (L) vs. high (H)). The Kaplan-Meier method was used for survival analysis. Univariable and multivariable Cox analyses were performed to determine the independent prognostic factors. Patients with LNLR had better survival than those with HNLR (median, 38.0 vs. 13.0, P<0.001). Patients with LSII had better survival (26.0 vs. 10.0 months, P=0.001) than those with HSII. The areas under the curves for NLR, LMR, PLR, SII, and ALP were 0.761 (P<0.001), 0.683 (P=0.012), 0.697 (P=0.002), 0.653 (P=0.031), and 0.515 (P=0.837), respectively. In the univariable analyses, Enneking's stage, systemic chemotherapy, surgery, NLR, PLR, LMR, and SII were associated with overall survival (OS). The multivariable analysis showed that HNLR (HR=2.507; 95% CI=1.364-4.606; P=0.003) was independent unfavorable prognostic factors. This preliminary study suggests that NLR is associated with poor prognosis in osteosarcoma. NLR could be a potential prognostic marker of osteosarcoma. IJCEP
Copyright © 2020.

Entities:  

Keywords:  Osteosarcoma; lymphocyte-monocyte ratio; neutrophil-lymphocyte ratio; platelet-lymphocyte ratio; prognosis; systemic immune-inflammation index

Year:  2020        PMID: 32269690      PMCID: PMC7137012     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  45 in total

1.  Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma.

Authors:  Xin Huang; Hongzhi Hu; Weiyue Zhang; Zengwu Shao
Journal:  J Cell Physiol       Date:  2019-03-19       Impact factor: 6.384

2.  Descriptive epidemiology of malignant primary osteosarcoma using population-based registries, United States, 1999-2008.

Authors:  Linh M Duong; Lisa C Richardson
Journal:  J Registry Manag       Date:  2013

Review 3.  Update on Survival in Osteosarcoma.

Authors:  Megan E Anderson
Journal:  Orthop Clin North Am       Date:  2016-01       Impact factor: 2.472

4.  The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.

Authors:  Mohammad Hosein Aziz; Kostandinos Sideras; Nasir Ahmad Aziz; Katya Mauff; Roel Haen; Daphne Roos; Lawlaw Saida; Mustafa Suker; Erwin van der Harst; Jan Sven Mieog; Bert A Bonsing; Yarne Klaver; Bas Groot Koerkamp; Casper H van Eijck
Journal:  Ann Surg       Date:  2019-07       Impact factor: 12.969

Review 5.  Osteosarcoma.

Authors:  Drew D Moore; Hue H Luu
Journal:  Cancer Treat Res       Date:  2014

6.  Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer.

Authors:  C-H Koh; N Bhoo-Pathy; K-L Ng; R S Jabir; G-H Tan; M-H See; S Jamaris; N A Taib
Journal:  Br J Cancer       Date:  2015-05-28       Impact factor: 7.640

7.  The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer.

Authors:  M Stotz; M Pichler; G Absenger; J Szkandera; F Arminger; R Schaberl-Moser; H Samonigg; T Stojakovic; A Gerger
Journal:  Br J Cancer       Date:  2013-12-19       Impact factor: 7.640

8.  Prognostic value of inflammation-based scores in patients with osteosarcoma.

Authors:  Bangjian Liu; Yujing Huang; Yuanjue Sun; Jianjun Zhang; Yang Yao; Zan Shen; Dongxi Xiang; Aina He
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

9.  Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma.

Authors:  Wen-Kai Xia; Zhi-Li Liu; Dong Shen; Qing-Feng Lin; Jun Su; Wei-Dong Mao
Journal:  World J Surg Oncol       Date:  2016-04-29       Impact factor: 2.754

Review 10.  Targeting VEGF/VEGFR to Modulate Antitumor Immunity.

Authors:  Ju Yang; Jing Yan; Baorui Liu
Journal:  Front Immunol       Date:  2018-05-03       Impact factor: 7.561

View more
  4 in total

Review 1.  Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.

Authors:  Tianyi Zhu; Jing Han; Liu Yang; Zhengdong Cai; Wei Sun; Yingqi Hua; Jing Xu
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

2.  Predictive value of the systemic immune-inflammation index for cancer-specific survival of osteosarcoma in children.

Authors:  Haiping Ouyang; Zhongliang Wang
Journal:  Front Public Health       Date:  2022-07-27

3.  Chitosan-Coated Titanium Dioxide-Embedded Paclitaxel Nanoparticles Enhance Anti-Tumor Efficacy Against Osteosarcoma.

Authors:  Yang Qu; Mingyang Kang; Xueliang Cheng; Jianwu Zhao
Journal:  Front Oncol       Date:  2020-09-09       Impact factor: 6.244

4.  Prognostic value of neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte ratios and Glasgow prognostic score in osteosarcoma: A meta-analysis.

Authors:  Li-Peng Peng; Jie Li; Xian-Feng Li
Journal:  World J Clin Cases       Date:  2022-03-06       Impact factor: 1.337

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.